Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
19/05/2026 12:01
May 19 (Reuters) - Tiziana Life Sciences Ltd TLSA.O: TIZIANA ANNOUNCES NEW POSITIVE CLINICAL DATA FOR INTRANASAL FORALUMAB IN NON-ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS TIZIANA ANNOUNCES NEW POSITIVE CLINICAL DATA FOR INTRANASAL FORALUMAB IN NON-ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS TIZIANA LIFE SCIENCES LTD - FORALUMAB WELL TOLERATED WITH NO NEW SAFETY SIGNALS IDENTIFIED TIZIANA LIFE SCIENCES LTD - INTRANASAL FORALUMAB WELL TOLERATED OVER EXTENDED TREATMENT AS OF MARCH 2026 Source text: ID:nGNX2qDZq1 Further company coverage: TLSA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis